(Reuters) -GE HealthCare Technologies raised its annual adjusted profit forecast and beat estimates for third-quarter results on Wednesday, powered by strong demand for its medical devices in the United States and the Europe, Middle East, and Africa region.
Over the past couple of years, medical device makers have benefited from more people, particularly older Americans, seeking healthcare services and surgical procedures.
The company now expects 2025 adjusted profit of $4.51 to $4.63 per share, 4 cents higher at the midpoint than its previous expected range of $4.43 to $4.63.
It reiterated expectations of a $265 million, or 45-cents-per-share, impact this year from President Donald Trump’s tariffs.
But the estimate now includes the administration’s 50% levies on India and certain tariffs on copper, steel and aluminum derivatives, GE HealthCare said on Wednesday.
Revenue in the imaging devices unit – the largest of its four segments – rose 5% to $2.35 billion in the third quarter.
Its other three businesses are advanced visualization solutions, patient care solutions and pharmaceutical diagnostics.
Total quarterly sales came in at $5.14 billion, compared with analysts’ average estimate of $5.08 billion, according to data compiled by LSEG.
Sales in China fell 3% to $547 million, still under pressure from business disruptions tied to Beijing’s anti-corruption crackdown on the healthcare sector, as well as delays in economic stimulus.
On an adjusted basis, GE HealthCare earned $1.07 per share during the quarter ended September 30, higher than estimates of $1.05 per share, but down 6 cents from last year due to a hit from tariffs.
(Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath)
